Incyte Corp (NAS:INCY)
$ 57.04 -0.01 (-0.02%) Market Cap: 12.83 Bil Enterprise Value: 9.01 Bil PE Ratio: 17.28 PB Ratio: 2.37 GF Score: 86/100

Incyte Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 13, 2021 / 03:45PM GMT
Release Date Price: $72.45 (+1.87%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Okay. Thank you, everyone, for joining. Let's go ahead and get started. My name is Vikram Purohit. I'm one of the biotech analysts with the Morgan Stanley research team here. And I'm very happy to have with me the team from Incyte for a 30-minute fireside chat.

Before we get started, I need to read a brief disclosure statement. So for important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your sales representative.

So with that, joining me virtually, I have Herve Hoppenot, CEO; Christiana Stamoulis, CFO; and Steven Stein, CMO, from Incyte. Thank you all for joining.

Herve Hoppenot
Incyte Corporation - Chairman, President & CEO

Thank you for inviting us. Good morning.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot